Clinical Trials Results - National Cancer Institute

Skip to content

National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?


	1-800-4-CANCER

	LiveHelp® online chat

	NCI Highlights


	High Dose Chemotherapy Prolongs Survival for Leukemia Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E Past Highlights



Results: 1 -6 of 6 Show results per page	View Search Criteria \| Help With Results


Sort By:	Version:	Format:

Last Modified: 11/14/2008 First Published: 11/20/2003


1.		Phase I/II Study of Vaccination With Autologous Monocyte-Derived Dendritic Cells Transfected With RNAs Encoding For Melan-A, MAGE-3, and Survivin Antigens in Patients With Stage IV Cutaneous Melanoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				18 and over				Other				ERLANGEN-DERMA-ER-DC-06 EU-20317, NCT00074230

Last Modified: 10/31/2008 First Published: 11/1/1999


2.		Phase II Study of Adoptive Transfer of Cloned Lymphocytes With Interleukin-2 After Cyclophosphamide and Fludarabine in Patients With Metastatic Melanoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				16 and over				NCI				NCI-99-C-0158 NCI-T99-0078, T99-0078, NCT00019942

Last Modified: 11/16/2008 First Published: 5/28/2004


3.		Phase II Study of Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody (MDX-010) and Peptide Vaccine Comprising Tyrosinase, gp100 Antigen, and MART-1 Antigen Emulsified in Montanide ISA-51 in Patients With Resected Stage III or IV Melanoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				18 and over				NCI, Pharmaceutical / Industry				MCC-15241 MDX-010-16, NCI-6446, 6446, NCT00084656, LAC-USC-10M036


4.		Immunotherapy of Melanoma Patients

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Active				18 and over				Other				LUD 1998-009 NCT00112216


5.		Immunotherapy of Stage III/IV Melanoma Patients

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Active				18 and over				Other				LUD 2001-003 NCT00112242


6.		Immunotherapy of Melanoma With Tumor Antigen RNA and Small Inhibitory RNA Transfected Autologous Dendritic Cells

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Active				Over 18				Other				Pro00000806 IND # BB-13545, NIH OBA # 0708-874, NCT00672542

Select All on One Page

| | | | | | | |

A Service of the National Cancer Institute